Adverum Biotechnologies Inc (ADVM)
6.96
-0.29
(-4.00%)
USD |
NASDAQ |
Nov 15, 11:22
Adverum Biotechnologies Cash and Short Term Investments (Quarterly): 153.24M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 153.24M |
| June 30, 2024 | 173.83M |
| March 31, 2024 | 193.33M |
| December 31, 2023 | 96.53M |
| September 30, 2023 | 117.08M |
| June 30, 2023 | 141.45M |
| March 31, 2023 | 164.28M |
| December 31, 2022 | 185.59M |
| September 30, 2022 | 203.26M |
| June 30, 2022 | 235.84M |
| March 31, 2022 | 271.06M |
| December 31, 2021 | 305.19M |
| September 30, 2021 | 332.70M |
| June 30, 2021 | 363.84M |
| March 31, 2021 | 404.02M |
| December 31, 2020 | 429.73M |
| September 30, 2020 | 454.46M |
| June 30, 2020 | 280.14M |
| March 31, 2020 | 297.07M |
| December 31, 2019 | 166.04M |
| September 30, 2019 | 161.98M |
| June 30, 2019 | 177.64M |
| Date | Value |
|---|---|
| March 31, 2019 | 189.49M |
| December 31, 2018 | 205.08M |
| September 30, 2018 | 217.88M |
| June 30, 2018 | 234.88M |
| March 31, 2018 | 247.04M |
| December 31, 2017 | 190.48M |
| September 30, 2017 | 186.64M |
| June 30, 2017 | 197.42M |
| March 31, 2017 | 209.50M |
| December 31, 2016 | 222.17M |
| September 30, 2016 | 231.27M |
| June 30, 2016 | 241.30M |
| March 31, 2016 | 247.08M |
| December 31, 2015 | 259.08M |
| September 30, 2015 | 268.89M |
| June 30, 2015 | 279.64M |
| March 31, 2015 | 290.12M |
| December 31, 2014 | 159.40M |
| September 30, 2014 | 165.33M |
| June 30, 2014 | 52.43M |
| March 31, 2014 | 50.68M |
| December 31, 2013 | 0.564M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
96.53M
Minimum
Dec 2023
454.46M
Maximum
Sep 2020
248.43M
Average
219.55M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 253.79M |
| Cassava Sciences Inc | 148.98M |
| Regenxbio Inc | 255.46M |
| Editas Medicine Inc | 265.09M |
| Apellis Pharmaceuticals Inc | 396.86M |